Dr. Nurulain Zaveri invited to speak at the Graduate Seminar at University of the Pacific in Stockton, CA, on November 17th, 2022. As the sole founder of Astraea Therapeutics, her mission for the company has been to develop oral medicines that could empower patients to overcome their substance addiction and reverse their vulnerability to relapse. She will be speaking about her journey "Concept-to-Clinic: Design and Development of First-in-class Drugs for Substance Use Disorders and Pain."
Dr. Nurulain Zaveri gave a Plenary talk at the European Federation for Medicinal Chemistry, 2019 MedChem Frontiers Symposium in Krakow, Poland, June 10-13, 2019. As a collaboration between the ACS (American Chemical Society) and the EFMC (European Federation for Medicinal Chemistry), this symposium attracts experts in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, early toxicology, as well as chemical and pharmaceutical development.
President and CSO of Astraea Therapeutics, Dr. Nurulain Zaveri, invited to speak on “Bifunctional NOP/MOP agonists as a new approach for non-addicting analgesics and treatments for Opioid Use Disorders,” at the 2019 International Narcotics Research Conference in New York, NY, July 7-11, 2019.